Vas Narasimhan, AP Images
February 2, 2022 01:31 PM ESTUpdated 03:28 PM
Pharma

Vas Narasimhan re­veals a dis­ap­point­ing out­look for No­var­tis' gener­ics unit, while lay­ing out the phar­ma's M&A strat­e­gy

Nicole DeFeudis

Editor

As No­var­tis CEO Vas Narasimhan fig­ures out ex­act­ly what he wants to do with San­doz, the com­pa­ny re­vealed in its Q4 re­port that US sales …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

A service from the Financial Times